Telix signs agreement with Radius for distribution of Illuccix in Italy

Author : Pankaj Singh | Published Date : 2021-09-13 
  • Radius will be the exclusive distributor for Illuccix in Italy for three years following the national approval date.
  • Radius and Telix Pharma had previously joined hands for the distribution of Ga-PSMA-11 for magisterial use in Italy.

Telix Pharmaceuticals Limited has reportedly entered into an agreement with Radius S.r.l for the exclusive commercial distribution of Illuccix, Telix’s prostate cancer imaging product, in Italy.

Under the terms of the contract, Radius will be the exclusive distributor for Illuccix in Italy for three years following the national approval date. The radiotherapy solutions provider had previously partnered with Telix Pharmaceuticals for the distribution of Ga-PSMA-11 for magisterial use in Italy.

It is also worth noting that Radius is the industry leader in the supply of gallium generators across Italy which enables it to provide a secure supply of the gallium required for launching Illuccix. The company is also a service provider and supplier for radiotherapy suites and cyclotrons across Italy which lends it a competitive edge.

Chief Executive Officer of Radius Dr. Mauro Mei was quoted saying that the partnership with Telix Pharmaceuticals will enable the company to provide state-of-the-art PSMA imaging facilities to the 39,000 men diagnosed with prostate cancer in Italy every year following the required regulatory approval.

EMEA President at Telix Pharmaceuticals Richard Valeix mentioned that Italy is an important market considering the high incidence of prostate cancer in the country. He further added that the partnership with Radius, which is already a renowned patient-centric company specializing in nuclear medicine, will enable Telix to achieve its mission of helping cancer patients live longer and better lives.

In 2020, prostate cancer was the most diagnosed type of cancer among Italian men with approximately 39,000 new cases being recorded. It was also a leading cause of cancer-related deaths among men in Italy with 7000 deaths registered during the year.

Source Credits--


About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Driivz and Hubject partner to deliver seamless EV charging experience

Published Date: 2021-09-22         Author: Pankaj Singh

Leading electric vehicle charging and smart energy management platform Driivz announced a partnership with the world’s global eRoaming provider Hubject to provide a seamless experience of Plug & Charge EV experience based on ISO 15118. The collaboration comes after European EV charging ... Read More

Design Café secures USD 25 million to expand into additional cities

Published Date: 2021-09-21         Author: Pankaj Singh

Home interior solutions provider Design Café has reportedly secured USD 25 million during an extended Series B funding round. This time the round was led by Westbridge Capital as well as Sixth Sense Ventures. Existing investor Fireside Ventures was also involved in the latest fundraising, ... Read More

Dubber acquires AI meeting solutions provider Notiv for USD 6.6 Mn

Published Date: 2021-09-20         Author: Pankaj Singh

Dubber, a cloud call recording service provider, has signed a deal worth USD 6.6 million to acquire Notiv, a Brisbane-based technology group. Notiv, previously owned by Pinch labs, develops products based on cloud-native artificial intelligence (AI) designed to convert meetings into transcribed n... Read More

© 2021 Fractovia. All Rights Reserved